ArticleJAMA network open2025
Short-Term Limited Duration Insurance Plan Policies and Cancer Stage at Diagnosis.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Importance: Many short-term limited duration (STLD) insurance plans do not cover essential health benefits, such as cancer screenings, potentially delaying diagnoses. In October 2018, federal regulations loosened restrictions on STLD plans by extending the allowable duration from 3 months to 36 months. States expanded, restricted, or eliminated the sale or terms of STLD plans, both prior to 2018 and afterwards. The association of state-level policies and late-stage cancer diagnosis is largely undocumented. Objective: To examine associations of state-level policies regarding STLD plans and late-stage cancer diagnosis before and after the 2018 federal rule. Design, Setting, and Participants: This cross-sectional study included adults aged 18 to 64 years newly diagnosed with cancer (January 2016 to February 2020) in 47 states and the District of Columbia from the National Cancer Database. Patients were grouped by state-level STLD plan policies: (1) states continuously prohibited STLD plans before and after 2018; (2) states stopped offering STLD plans after 2018; (3) states allowed the sale of STLD plans with additional restrictions to the 2018 federal rules; (4) states with no additional STLD regulation. Difference-in-differences analyses were conducted to evaluate changes in late-stage diagnoses (stages III/IV) pre-2018 (January 2016 to June 2018) and post-2018 (January 2019 to February 2020) for groups 2, 3, and 4 vs group 1 for all cancers combined and for 5 common cancers, adjusting for sociodemographic factors (age group, sex, metropolitan status, zip code-level poverty), diagnosis year, and state random effect. All analyses were performed from May 2023 to January 2025. Exposures: State-level STLD plan policies. Main Outcomes and Measures: Change in percentages of late-stage cancer diagnosis. Results: Among 1 289 366 adults newly diagnosed with cancer (mean [SD] age, 53 [9.2] years; 536 514 [41.6%] female; 73 061 [5.7%] Hispanic, 110 564 [8.6%] non-Hispanic Asian and Pacific Islander and other, 172 246 [13.4%] non-Hispanic Black, 921 722 [71.5%] non-Hispanic White), 604 882 (46.9%) were from group 4 states (no additional STLD regulations). Group 4 had a net increase of 0.76 (95% CI, 0.22-1.29) percentage points (P = .01) and group 3 (some STLD regulations) had a net increase of 0.84 (95% CI, 0.26-1.42) percentage points (P = .005) in late-stage diagnoses compared with group 1 (continuously prohibited STLD plans). Similar patterns were observed for female breast and colorectal cancers. Conclusions and Relevance: In this cross-sectional study of state-level policies regarding STLD plans and late-stage cancer diagnosis, loosened federal restrictions on STLD plans in 2018 were associated with a net increase in late-stage cancer diagnoses in states without or with inadequate regulatory protections, underscoring the critical role of state policies in regulating STLD plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.